Revelation Biosciences Inc (REVB)

$0.90 -0.01 (-0.57%)
Market Cap 5.33M
Revenue (ttm) 0.00
Net Income (ttm) -15.04M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 109,200
Avg Vol 114,060
Day's Range N/A - N/A
Shares Out 5.92M
Stochastic %K 85%
Beta -0.14
Analysts Strong Sell
Price Target $21.25

Company Profile

Revelation Biosciences, Inc. operates as a clinical-stage biopharmaceutical company that focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was formerly known as Petra Acquisition, Inc. and changed...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 800 3717
Address:
4660 La Jolla Village Drive, Suite 100, San Diego, United States
jsmith14
jsmith14 Jan. 15 at 1:10 AM
$REVB I suspect something is cooking here!
0 · Reply
jsmith14
jsmith14 Jan. 14 at 8:56 PM
$REVB last reported to have approx 12 mil cash on hand, low total liabilities. More cash than current market cap. Fundamentals look good for a small cap.
0 · Reply
RainManCash
RainManCash Jan. 14 at 3:29 PM
$REVB added here based on the positive clinical data for Gemini in kidney disease treatment…. I am going against my trading plan here on biosciences, I never hold them in my portfolio only scalp them; making an exception for $REVB
0 · Reply
jsmith14
jsmith14 Jan. 14 at 1:34 AM
$REVB took small pos here, I like a stable grind back up
0 · Reply
SinglesOverHomeRun
SinglesOverHomeRun Jan. 13 at 11:02 PM
$REVB
0 · Reply
revuelto
revuelto Jan. 13 at 3:12 PM
$REVB a spike would be greatly appreciated 😀✌️
0 · Reply
JesusJunkie77
JesusJunkie77 Jan. 12 at 5:41 PM
$REVB Could see a move like $ASST herr real soon.
0 · Reply
JoNCherry
JoNCherry Jan. 9 at 10:15 PM
$REVB https://www.investing.com/news/company-news/revelation-biosciences-begins-gmp-manufacturing-for-gemini-trials-93CH-4435199
0 · Reply
KennyIsRisen
KennyIsRisen Jan. 7 at 2:59 PM
$REVB Interested in getting into this after some other plays. Watching though and have been for a while.
0 · Reply
SinglesOverHomeRun
SinglesOverHomeRun Jan. 7 at 2:16 PM
$REVB
0 · Reply
Latest News on REVB
Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2026)

Jan 14, 2026, 9:00 AM EST - 12 hours ago

Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2026)

Revelation Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jan 12, 2026, 5:00 PM EST - 2 days ago

Revelation Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Revelation Biosciences Announces Initiation of GMP Manufacturing of GEMINI and Placebo to Support Later Stage Clinical Development

Jan 7, 2026, 9:00 AM EST - 7 days ago

Revelation Biosciences Announces Initiation of GMP Manufacturing of GEMINI and Placebo to Support Later Stage Clinical Development

Revelation Biosciences Has Reached A Quorum For Its December 3, 2025 Special Meeting

Dec 1, 2025, 9:00 AM EST - 6 weeks ago

Revelation Biosciences Has Reached A Quorum For Its December 3, 2025 Special Meeting

Revelation Biosciences On Track for End-of-Phase 1 Meeting With FDA Later This Year

Nov 20, 2025, 9:00 AM EST - 7 weeks ago

Revelation Biosciences On Track for End-of-Phase 1 Meeting With FDA Later This Year

Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2025

Nov 6, 2025, 4:15 PM EST - 2 months ago

Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2025

Revelation Biosciences Inc. Announces Cancellation of Adjournment of October 29, 2025 Special Meeting of Stockholders and New Record Date

Oct 29, 2025, 9:00 AM EDT - 2 months ago

Revelation Biosciences Inc. Announces Cancellation of Adjournment of October 29, 2025 Special Meeting of Stockholders and New Record Date

Revelation Biosciences Inc. Announces Adjournment of October 15, 2025 Special Meeting of Stockholders to October 29, 2025

Oct 15, 2025, 5:00 PM EDT - 3 months ago

Revelation Biosciences Inc. Announces Adjournment of October 15, 2025 Special Meeting of Stockholders to October 29, 2025

Revelation Biosciences Inc. Announces Exercise of Warrants for $9.6 Million in Gross Proceeds

Sep 11, 2025, 8:30 AM EDT - 4 months ago

Revelation Biosciences Inc. Announces Exercise of Warrants for $9.6 Million in Gross Proceeds

Revelation Biosciences Announces Special Webcast to Review Positive Top-line Clinical Data

Sep 10, 2025, 7:20 AM EDT - 4 months ago

Revelation Biosciences Announces Special Webcast to Review Positive Top-line Clinical Data

Reminder - Webcast/Conference Call to Discuss Fantastic PRIME Phase 1b Top-line Data

Sep 9, 2025, 4:55 PM EDT - 4 months ago

Reminder - Webcast/Conference Call to Discuss Fantastic PRIME Phase 1b Top-line Data

Revelation Biosciences Announces Groundbreaking Top-line Results from PRIME Clinical Study

Sep 9, 2025, 8:00 AM EDT - 4 months ago

Revelation Biosciences Announces Groundbreaking Top-line Results from PRIME Clinical Study

Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2025

Aug 8, 2025, 6:30 AM EDT - 5 months ago

Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2025

Revelation Biosciences, Inc. Congratulates Its Former Chairman of the Board, George Tidmarsh, on His Appointment as the Head of the FDA Center for Drug Evaluation and Research

Jul 24, 2025, 9:00 AM EDT - 6 months ago

Revelation Biosciences, Inc. Congratulates Its Former Chairman of the Board, George Tidmarsh, on His Appointment as the Head of the FDA Center for Drug Evaluation and Research

Revelation Biosciences Inc. Completes Dosing of Patients in PRIME Study

Jul 16, 2025, 9:00 AM EDT - 6 months ago

Revelation Biosciences Inc. Completes Dosing of Patients in PRIME Study

Revelation Biosciences Inc. Announces 1-for-3 Reverse Stock Split Effective July 7, 2025

Jul 1, 2025, 5:26 PM EDT - 7 months ago

Revelation Biosciences Inc. Announces 1-for-3 Reverse Stock Split Effective July 7, 2025

Revelation Biosciences, Inc. Announces Closing of $4 Million Public Offering

May 29, 2025, 4:05 PM EDT - 8 months ago

Revelation Biosciences, Inc. Announces Closing of $4 Million Public Offering

Revelation Biosciences, Inc. Announces Pricing of $4 Million Public Offering

May 29, 2025, 8:00 AM EDT - 8 months ago

Revelation Biosciences, Inc. Announces Pricing of $4 Million Public Offering

Revelation Biosciences Announces Retirement of George Tidmarsh, MD, PhD from Board of Directors

May 23, 2025, 4:05 PM EDT - 8 months ago

Revelation Biosciences Announces Retirement of George Tidmarsh, MD, PhD from Board of Directors

Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2025

May 8, 2025, 4:15 PM EDT - 8 months ago

Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2025

Revelation Biosciences to Develop Gemini for Infection in Severe Burn Patients

Apr 29, 2025, 9:00 AM EDT - 9 months ago

Revelation Biosciences to Develop Gemini for Infection in Severe Burn Patients

Gemini Priming Attenuates Inflammation in Human Peripheral Blood Mononuclear Cells

Mar 17, 2025, 6:00 AM EDT - 10 months ago

Gemini Priming Attenuates Inflammation in Human Peripheral Blood Mononuclear Cells

Revelation Biosciences to Host Fireside Chat at 37th Annual Roth Conference

Mar 13, 2025, 6:00 AM EDT - 10 months ago

Revelation Biosciences to Host Fireside Chat at 37th Annual Roth Conference

Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2024

Mar 6, 2025, 4:15 PM EST - 11 months ago

Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2024

Revelation Biosciences Doses First Patient in PRIME Phase 1b Clinical Study of Gemini in CKD Patients

Feb 26, 2025, 6:00 AM EST - 11 months ago

Revelation Biosciences Doses First Patient in PRIME Phase 1b Clinical Study of Gemini in CKD Patients

Revelation Biosciences, Inc. Receives Continued NASDAQ Listing Approval

Feb 24, 2025, 6:00 AM EST - 11 months ago

Revelation Biosciences, Inc. Receives Continued NASDAQ Listing Approval

Revelation Biosciences Inc. Announces 1-for-16 Reverse Stock Split Effective January 28, 2025

Jan 24, 2025, 6:00 AM EST - 1 year ago

Revelation Biosciences Inc. Announces 1-for-16 Reverse Stock Split Effective January 28, 2025

Revelation Biosciences Starts its PRIME Phase 1b Clinical Study of Gemini in CKD Patients

Jan 21, 2025, 6:00 AM EST - 1 year ago

Revelation Biosciences Starts its PRIME Phase 1b Clinical Study of Gemini in CKD Patients

Revelation Biosciences Inc. Reminds You to Vote for the Special Meeting on January 17, 2025

Jan 13, 2025, 6:00 AM EST - 1 year ago

Revelation Biosciences Inc. Reminds You to Vote for the Special Meeting on January 17, 2025

Nasdaq Grants Revelation Biosciences Inc. Continued Listing

Jan 6, 2025, 6:00 AM EST - 1 year ago

Nasdaq Grants Revelation Biosciences Inc. Continued Listing

Revelation Biosciences Inc. Announces Exercise of Warrants for $4 Million in Gross Proceeds

Dec 3, 2024, 8:38 AM EST - 1 year ago

Revelation Biosciences Inc. Announces Exercise of Warrants for $4 Million in Gross Proceeds

Revelation Biosciences Inc. Announces FDA Acceptance of Gemini IND

Dec 2, 2024, 6:00 AM EST - 1 year ago

Revelation Biosciences Inc. Announces FDA Acceptance of Gemini IND

Revelation Biosciences, Inc. Completes the GMP Manufacture of Gemini Clinical Drug Supply

Nov 12, 2024, 6:00 AM EST - 1 year ago

Revelation Biosciences, Inc. Completes the GMP Manufacture of Gemini Clinical Drug Supply

Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2024

Nov 8, 2024, 4:15 PM EST - 1 year ago

Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2024

Revelation Biosciences' Gemini Induces Dose Dependent Significant Increases in IL-10

Sep 24, 2024, 6:00 AM EDT - 1 year ago

Revelation Biosciences' Gemini Induces Dose Dependent Significant Increases in IL-10

Revelation Biosciences Inc. Announces Exercise of Warrants for $3.8 Million in Gross Proceeds

Aug 21, 2024, 5:30 PM EDT - 1 year ago

Revelation Biosciences Inc. Announces Exercise of Warrants for $3.8 Million in Gross Proceeds

Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2024

Aug 9, 2024, 4:15 PM EDT - 1 year ago

Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2024

Revelation Biosciences Announces Phase 1 Clinical Study of Gemini Met the Primary Safety Endpoint and Showed Statistically Significant Biomarker Activity

Jun 24, 2024, 9:00 AM EDT - 1 year ago

Revelation Biosciences Announces Phase 1 Clinical Study of Gemini Met the Primary Safety Endpoint and Showed Statistically Significant Biomarker Activity

Revelation Biosciences Has Completed Dosing of its First in Human Phase 1 Clinical Study of Gemini

Jun 13, 2024, 9:21 AM EDT - 1 year ago

Revelation Biosciences Has Completed Dosing of its First in Human Phase 1 Clinical Study of Gemini

Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2024

May 10, 2024, 4:52 PM EDT - 1 year ago

Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2024

Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2023

Mar 22, 2024, 4:15 PM EDT - 1 year ago

Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2023

Revelation Biosciences Inc. Gives Oral Presentation at Advances in Critical Care Nephrology (AKI & CRRT 2024)

Mar 13, 2024, 9:00 AM EDT - 2 years ago

Revelation Biosciences Inc. Gives Oral Presentation at Advances in Critical Care Nephrology (AKI & CRRT 2024)

Revelation Biosciences Inc. to Participate in a Virtual Fireside Chat at the 36th Annual Roth Conference

Mar 12, 2024, 9:00 AM EDT - 2 years ago

Revelation Biosciences Inc. to Participate in a Virtual Fireside Chat at the 36th Annual Roth Conference

Revelation Biosciences Inc. Announces Commencement of First in Human Phase 1 Clinical Study of Gemini

Mar 4, 2024, 9:00 AM EST - 2 years ago

Revelation Biosciences Inc. Announces Commencement of First in Human Phase 1 Clinical Study of Gemini

Revelation Biosciences Inc. Receives Invitation to Give an Oral Presentation at The 29th International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024)

Feb 13, 2024, 9:00 AM EST - 2 years ago

Revelation Biosciences Inc. Receives Invitation to Give an Oral Presentation at The 29th International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024)

Top 5 Health Care Stocks That Are Preparing To Pump In February

Feb 9, 2024, 8:35 AM EST - 2 years ago

Top 5 Health Care Stocks That Are Preparing To Pump In February

CNSP GILD ZLAB

Revelation Biosciences Inc. Announces Closing of $6.2 Million Public Offering

Feb 5, 2024, 4:41 PM EST - 2 years ago

Revelation Biosciences Inc. Announces Closing of $6.2 Million Public Offering

Revelation Biosciences Inc. Announces Pricing of $6.2 Million Public Offering

Feb 1, 2024, 6:00 AM EST - 2 years ago

Revelation Biosciences Inc. Announces Pricing of $6.2 Million Public Offering

Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024)

Jan 30, 2024, 9:00 AM EST - 2 years ago

Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024)

Revelation Biosciences Inc. Announces 1-for-30 Reverse Stock Split Effective January 25, 2024

Jan 23, 2024, 9:00 AM EST - 2 years ago

Revelation Biosciences Inc. Announces 1-for-30 Reverse Stock Split Effective January 25, 2024

jsmith14
jsmith14 Jan. 15 at 1:10 AM
$REVB I suspect something is cooking here!
0 · Reply
jsmith14
jsmith14 Jan. 14 at 8:56 PM
$REVB last reported to have approx 12 mil cash on hand, low total liabilities. More cash than current market cap. Fundamentals look good for a small cap.
0 · Reply
RainManCash
RainManCash Jan. 14 at 3:29 PM
$REVB added here based on the positive clinical data for Gemini in kidney disease treatment…. I am going against my trading plan here on biosciences, I never hold them in my portfolio only scalp them; making an exception for $REVB
0 · Reply
jsmith14
jsmith14 Jan. 14 at 1:34 AM
$REVB took small pos here, I like a stable grind back up
0 · Reply
SinglesOverHomeRun
SinglesOverHomeRun Jan. 13 at 11:02 PM
$REVB
0 · Reply
revuelto
revuelto Jan. 13 at 3:12 PM
$REVB a spike would be greatly appreciated 😀✌️
0 · Reply
JesusJunkie77
JesusJunkie77 Jan. 12 at 5:41 PM
$REVB Could see a move like $ASST herr real soon.
0 · Reply
JoNCherry
JoNCherry Jan. 9 at 10:15 PM
$REVB https://www.investing.com/news/company-news/revelation-biosciences-begins-gmp-manufacturing-for-gemini-trials-93CH-4435199
0 · Reply
KennyIsRisen
KennyIsRisen Jan. 7 at 2:59 PM
$REVB Interested in getting into this after some other plays. Watching though and have been for a while.
0 · Reply
SinglesOverHomeRun
SinglesOverHomeRun Jan. 7 at 2:16 PM
$REVB
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 2 at 1:42 AM
$REVB RSI: 22.33, MACD: -0.0551 Vol: 0.10, MA20: 0.95, MA50: 1.01 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
SinglesOverHomeRun
SinglesOverHomeRun Dec. 30 at 8:12 PM
$REVB it seems the rumor is they are out in the wind until the new year. no wonder is dropped from that recent rise. Typical small cap- promises made, promises can't be kept. all talk no substance.
0 · Reply
revuelto
revuelto Dec. 29 at 8:54 PM
$REVB looks primed for an upside move…..will be an attractive short setup when that happens✌️
0 · Reply
StrategistBrady
StrategistBrady Dec. 29 at 6:39 AM
$REVB 1.25+ retrace possible
0 · Reply
SinglesOverHomeRun
SinglesOverHomeRun Dec. 22 at 3:06 PM
$REVB ticker trading as if FDA told them to fuq off
0 · Reply
AlwaysLearning72
AlwaysLearning72 Dec. 21 at 4:14 PM
$REVB hopefully we receive some positive news from their FDA meeting soon
1 · Reply
SinglesOverHomeRun
SinglesOverHomeRun Dec. 19 at 3:56 PM
$REVB
0 · Reply
revuelto
revuelto Dec. 18 at 8:18 PM
$REVB sell the pop, short the ….you know the drill…anyone who’s done some study here can see this is a sham operation ✌️
1 · Reply
revuelto
revuelto Dec. 15 at 7:50 PM
$REVB it has to close above $1, if it doesn’t, likely heading much lower i.e. short it ✌️
1 · Reply
Love_To_Learn
Love_To_Learn Dec. 15 at 1:26 PM
$REVB ive changed your 1.18 1.17 res btw so take note of that longs * place it on your chart detour of sorts
1 · Reply
thatboytrades
thatboytrades Dec. 13 at 1:32 AM
$REVB holding a nice chunk of long position here
0 · Reply
SPYmyQQQ
SPYmyQQQ Dec. 12 at 12:33 AM
🎯 Target Hit 🏁 📨 From Nov 6, 2025 💊 $REVB 💵 Entry: $1.0000 ✅ Ext: $1.1900 💰 P/L: +19.00% 👉 FREE TRIAL! spymyqqq/join/
0 · Reply